Treatment of ST-elevation myocardial infarction in China: Where are we?

Similar documents
SHOULD A REGIONAL STEMI CENTRE ONLY OFFER PRIMARY PCI?

NEBRASKA STEMI CONFERENCE 2015 Dr. Doug Kosmicki. 2013, American Heart Association

Management of STEMI in era of Reperfusion. Eagles Peter Moyer, MD, MPH Medical Director Boston EMS, Fire and Police

Regional STEMI Transfer Systems: the Mayo and NC RACE Experiences

The Window for Fibrinolysis. Frans Van de Werf, MD, PhD Leuven, Belgium

Acute Coronary Syndrome

Pharmaco-Invasive Approach for STEMI

Patient and System Time Delay

Coronary Catheterization and Percutaneous Coronary Intervention in China 10-Year Results From the China PEACE-Retrospective CathPCI Study

The Role of DHMC as an ST Elevation Myocardial Infarction Receiving Center in a Regional STEMI Care Network:

REFERRAL HOSPITAL. The Importance of Door In Door Out Time DIDO

Primary Percutaneous Coronary Intervention

Daily practice of ACS management in the Gulf: Data from Gulf COAST

Controversies on Primary angioplasty in STEMI

GUIDELINE 14 ACUTE CORONARY SYNDROMES

Downloaded from:

Recommendations for criteria for STEMI systems of care: A focus on pharmacoinvasive strategies

The Burden & Management of Ischaemic Heart Disease in Kenya

William D. Salerno, M.D. Director, Coronary Care Unit Hackensack University Medical Center Clinical Associate Professor of Medicine, UMDNJ

Current Advances and Best Practices in Acute STEMI Management A pharmacoinvasive approach

STREAM - ONE YEAR MORTALITY STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION. STREAM 1Y AHA 2013 P Sinnaeve

CLINICIAN INTERVIEW RECOGNIZING ACS AND STRATIFYING RISK IN PRIMARY CARE. An interview with A. Michael Lincoff, MD, and Eric R. Bates, MD, FACC, FAHA

Transfer in D2B. Scott D Friedman, MD FACC Medical Director, Cardiology Services Shore Health System of Maryland. The Problem

Literature Review and Recommendations Prehospital Fibrinolytics Administration for Acute Myocardial Infarction

2010 ACLS Guidelines. Primary goals of therapy for patients

Mark C. Bieniarz, MD Andrew Harrell, MD Peter Berger, MD

Improving the Outcomes of

Rural Minnesota STEMI Systems of Care

Dashboard and Outcomes Report with Case Studies

STEMI Presentation and Case Discussion. Case #1

Improving STEMI outcomes in Denmark. Michael Rahbek Schmidt, MD, PhD. Aarhus University Hospital Skejby Denmark

Decision for fibrinolysis or primary PCI in the prehospital phase

1 a) Please confirm or deny whether your Trust has admitted patients for acute myocardial infarction in 2008/09, 2009/10 or 2010/11

4. Which survey program does your facility use to get your program designated by the state?

GWTG-CAD: Mission: Lifeline Focus July 2017 PMT FORM SELECTION. Pre-Hospital/Arrival

ACUTE CORONARY SYNDROME PCI IN THE ELDERLY

Hot Topics in Cardiac Arrest. Should the patient go To the Cath Lab?

Thrombolysis in Cardiology to whom? Professor Steen D. Kristensen, MD, DMSc, FESC Department of Cardiology

Critics of Thrombolytics: Is Pre-Hospital Clot-busting Actually a Bad Thing? David Persse, MD Houston Fire Department EMS

ST-elevation myocardial infarctions (STEMIs)

Facilitated Percutaneous Coronary Intervention in Acute Myocardial Infarction. Is it beneficial to patients?

Conflits d intérêt Astra-Zeneca, BMS, MSD, Novartis, Pfizer, Daiichi-Sankyo, Servier, CRAM, AFSSAPS, ARH Région de Bourgogne Clos Vougeot

Quality Standards for Patients Treated by PCI. Peter F Ludman

Level One STEMI Connecting the Dots changing Points of Care into Systems of Care

The Strategic Reperfusion Early After STEMI study Implications for clinical practice

ST Elevated Myocardial Infarction- Latest AHA recommendations

Know the Quality of our Care at Every Step. Kansas City ACS Summit BI-State Cardiovascular Education Consortium

ACTION Registry GWTG Research and Publications Update

STEMI Care 2014 at the Crossroads: Taking the right road

EXTRACT FOR USE BY NORTH WEST AMBULANCE SERVICE PARAMEDICS

Background- Methods-

Implementation of myocardial system of care in a rural area in Brazil using telecardiology

Myocardial Infarction In Dr.Yahya Kiwan

THE EVIDENCED BASED 2015 CPR GUIDELINES

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?

Chapter 3 for 12 Lead Training -Precourse-

S. CHASSAING4 P. DEQUENNE5

Medical Management of Acute Coronary Syndrome: The roles of a noncardiologist. Norbert Lingling D. Uy, MD Professor of Medicine UERMMMCI

Earlier reperfusion in patients with ST-elevation Myocardial infarction by use of helicopter

Acute Coronary Syndromes

Reperfusion Strategy in Europe: Temporal Trends in Performance Measures for Reperfusion Therapy in ST Elevation Myocardial Infarction

Stent For Life, Egypt A Success Story. Hany Ragy MD, FSCAI NHI, Cairo,

Cardiology Department. Clinical Governance

10-Year Mortality of Older Acute Myocardial Infarction Patients Treated in U.S. Community Practice

THE BRIDGE-ACS TRIAL

Acute Coronary syndrome

STEMI Stents What next? Arshad Khan - HNE Clinical Research Fellow. Supervisors: Prof Boyle and Attia.

Presenters: Disclaimer. Definitions. Deanna Jones, RN, CCRN. Annmarie Keck, RN, CEN

PHARMACO-INVASIVE STRATEGY COMPARED WITH PPCI: DESIGN AND MAIN OUTCOMES OF THE STREAM TRIAL

Mode of admission and its effect on quality indicators in Belgian STEMI patients

Effect of upstream clopidogrel treatment in patients with ST-segment elevation myocardial infarction undergoing primary PCI

Li J, Li X, Ross JS, Wang Q, Wang Y, Desai NR, Xu X, Nuti SV, Masoudi FA, Spertus JA, Krumholz HM, Jiang L; China PEACE Collaborative Group.

Management of Acute Myocardial Infarction

DISCUSSION QUESTION - 1

Trauma Service Area - B (BRAC) Regional Cardiac Plan

Frans Van de Werf, MD, PhD Leuven, Belgium

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Advancing Stroke Systems of Care to Improve Outcomes Update on Target: Stroke Phase II

Chest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham

Out-of-hospital Cardiac Arrest. Franz R. Eberli MD, FESC, FAHA Cardiology Triemli Hospital Zurich, Switzerland

Mission: Lifeline Addressing the System of STEMI Care

2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction

The Need for Rescue PCI after Failed Fibrinolysis: Who, When and Why.

Is it safe to discharge patients 24 hours after uncomplicated successful primary percutaneous coronary intervention

The Changing Epidemiology of Acute Coronary Syndromes: Implications for practice: Dr. Sonia Anand, McMaster University

12/18/2009 Resting and Maxi Resting and Max mal Coronary Blood Flow 2

Post-Reteplase Evaluation of Clinical Safety & Efficacy in Indian Patients (Precise-In Study)

Xi Li, Jing Li, Frederick A Masoudi, John A Spertus, Zhenqiu Lin, Harlan M Krumholz, Lixin Jiang for the China PEACE Collaborative Group

Ischemic Heart Disease Interventional Treatment

Overcoming the Risk-Treatment Paradox in Non-STE ACS: It s Time! Christopher Granger, MD

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

GET WITH THE GUIDELINES- PAST AND FUTURE

2017 AHA/ACC Clinical Performance and Quality Measures for Adults With ST-Elevation and Non ST-Elevation Myocardial Infarction

New Insights on Reperfusion Choices Implications of STREAM. Paul W Armstrong MD

Patient characteristics Intervention Comparison Length of followup

Version 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM

Subsequent management and therapies

Acute Coronary Syndrome. Sonny Achtchi, DO

STEMI ST Elevation Myocardial Infarction

Quale terapia antiaggregante nello STEMI? Prasugrel vs ticagrelor

Transcription:

Treatment of ST-elevation myocardial infarction in China: Where are we? Associate Professor, Yihong Sun, MD Peking University People s Hospital Beijing, China

Disclosure conflict of Interest

The Challenges of Coronary Artery Disease in China Predicted annual total CHD deaths (CHD Policy Model-China) Circ Cardiovasc Qual Outcomes. 2010 May;3(3):243-52.

Hospitalized STEMI Treatment in Europe Data from National Registries or Surveys (2007-2008) In-hospital Mortality: 4.2-13.5% European Heart Journal (2010) 31, 943 957

Rapid increase in Percutaneous Coronary Interventions in China Over 300,000 PCI in 2011! Heart 2010;96:415-418

Numbers of patients receiving PCI in China in 2010 Zhang et al. / J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2011 12(8):629-632

Reperfusion Therapy of STEMI in China 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% GRACE China(2001-2003) CPACS(2004-2005) BRIG(2006) BEIJING(2006) NO TT PPCI Gao, et al. Heart 2008;94:554-560 Zhao, et al. Chin J Cardil, 2009;37:213-217 Hu, et al. Clin Invest Med 2008;31:e189-97 Lv,et al. Chin J Cardiol, 2005,33,789-82

Trend in patients with D to B <90mins in US Circulation. 2011;124:1038-1045

European Heart Journal doi:10.1093/eurheartj/ehs215

Time Delay of Reperfusion Therapy of STEMI in China BEIJING(L3*) BRIG(L3) BRIG(L2) CAPACS(L3) prehospital dalay D2B D2N CAPACS(L2) 0 50 100 150 200 250 300 Median time (minutes) Gao, et al. Heart 2008;94:554-560 Zhao, et al. Chin J Cardil, 2009;37:213-217 Hu, et al. Clin Invest Med 2008;31:e189-97 Lv,et al. Chin J Cardiol, 2005,33,789-82

The Registry of Reperfusion Therapy in Patients with STEMI in Beijing 18 million residents 19 hospitals with capability of primary PCI 16 centers in urban 3 centers in rural area From Nov 2005 to Dec 2006 Clin Invest Med. 2008,31(4):E189-97

Clin Invest Med. 2008,31(4):E189-97 Patient Characteristics by Reperfusion Strategy Data of Beijing Registry 2006 Total N=809 PPCI n=521 TT n=133 No n=155 Age (years) 60.9±12.7 60.1±12.4 58.5±11.3 65.3±13.6 <0.001 Age >75 135(16.9) 74(14.2) 9(7.2) 52(33.5) <0.001 Female 178(22.3) 105(20.2) 26(20.8) 47(30.5) 0.02 Smoking 446(56.5) 304 (59.5) 81(65.9) 61(39.45) <0.001 Diabetes 158(19.9) 92(17.9) 25(20.2) 41(26.5) 0.18 Hypertension 414(51.9) 226(51.3) 60(48.0) 88(57.1) 0.04 hypercholestoremia 162(20.4) 102(19.8) 26(20.8) 34(22.4) 0.63 Prior MI 74(9.3) 31(6.0) 19(15.2) 24(15.6) <0.001 CKD 14(1.8) 8(1.5) 0(0) 6(3.9) 0.006 Prior stroke 81(10.2) 50 (9.7) 9 (7.3) 22 (14.2) 0.10 Prior HF 10(1.3) 4(0.8) 2(1.6) 4(2.6) 0.09 p

Patient Characteristics by Reperfusion Strategy Data of Beijing Registry 2006 Off-hour presentation Total N=809 PPCI n=521 TT n=133 No n=155 520(64.9) 333(63.9) 86(68.8) 101(65.2) 0.59 p Pre-hospital ECG 291(35.9) 205(41.5) 42(34.4) 44(30.3) 0.03 EMS transport 310(38.7) 221(42.4) 43 (34.4) 46(29.7) 0.01 Pre-hospital delay >3h 351(44.2) 223(43.1) 41(33.3) 87(56.1) <0.001 Clin Invest Med. 2008,31(4):E189-97

Evidence Based Medication in Hospital Data of Beijing Registry 2006 Total N=809 PPCI n=521 TT n=133 No n=155 p Aspirin 774(98.1) 503(97.7) 121(99.2) 150(98.7) 0.46 Clopidogrel 701(90.0) 496(96.9) 96(81.4) 109(73.2) <0.001 UFH 211(27.5) 127(25.4) 63(52.9) 21(14.3) <0.001 LMWH 717(91.8) 481(94.5) 103(85.1) 133(88.1) 0.001 B-blocker 593(76.1) 397(77.7) 85(71.4) 111(74.5) 0.31 ACEI 559(72.5) 368(73.3) 88(72.2) 103(69.6) 0.67 Statin 716(91.6) 484(94.7) 102(85.0) 130(86.1) <0.001 Clin Invest Med. 2008,31(4):E189-97

In Hospital Outcomes by Reperfusion Strategy Data of Beijing Registry 2006 Total N=809 PPCI n=521 TT n=133 No n=155 p Death 37(4.6) 16(3.1) 7(5.6) 14(9.0) 0.001 Re-infarction 13(1.7) 8(1.6) 3(2.7) 2(1.4) 0.71 Stroke 3(0.4) 1(0.2) 1(0.9) 1(0.7) 0.47 New Heart failure 114(15.0) 68(13.5) 22(19.3) 24(16.9) 0.22 Severe Bleeding 17(2.3) 12(2.4) 2(1.8) 3(2.2) 0.91 Clin Invest Med. 2008,31(4):E189-97

Time from onset of symptoms to Treatment Data of Beijing Registry 2006 Onset of symptom On scene departure In hospital treatment In hospital fibrinolysis 130 min 30 min D to N 87.5mins Primary PCI 137 min 25 min D to B 137mins Hospital arrival Clin Invest Med. 2008,31(4):E189-97

Pre-hospital Delay (symptom onset to hospital arrival) Data of Beijing Registry 2006 >6hours 2-6 hours <2 hours 0 10 20 30 40 50 % Clin Invest Med. 2008,31(4):E189-97

The social-economic factors associated with Pre-hospital Delay Data of Beijing Registry 2006 Variable Pre-hospital delay 2h N=364 Pre-hospital delay >2h N=445 P Age (mean, y) 59.40 ±12.51 62.35 ±12.48 0.001 Age 65 y 128 (35.16) 189 (42.47) 0.034 Female 74 (20.73) 108 (25.35) 0.127 Health insurance 224(61.5) 294(66.1) 0.039 Education 167(45.9) 245(55.1) 0.403 Income >2000RMB/M 73(20.1) 123(27.6) 0.447 Clin Invest Med. 2008,31(4):E189-97

The risk factors associated with Pre-hospital Delay Data of Beijing Registry 2006 Variable OR 95% CI P Nitrate on symptom onset 8.666 2.312, 32.476 0.0071 No severe symptom 2.132 1.264, 3.597 0.0045 Symptom persist <30mins 25.0 1.786, 595.2 0.0281 Self transport 2.62 1.57, 4.37 0.0002 Clin Invest Med. 2008,31(4):E189-97

The Delay of Door to reperfusion Time Data of Beijing Registry 2006 >240 mins >180 min 180-240 mins 120-180 min 120-180 mins 90-120 min 90-120 mins 69-90 min 60-<90 min <60 min 20% 30-60 min <30 min 0 10 20 30 40 D to B 0 5 10 15 20 25 D to N Clin Invest Med. 2008,31(4):E189-97

The Delay of Door to reperfusion Time Data of Beijing Registry 2006 D to B >90 mins p value D to n >30 mins p value Low volume PCI center 0.0153 Age >65 0.0418 Off hour presentation Referral 0.0412 0.0304 HF(kiliip 4) Prehospital delay >2 h 0.041 0.0105 0 1 2 3 4 5 Odds ratio(95%ci) 0 1 2 3 4 5 Odds ratio(95%ci) Clin Invest Med. 2008,31(4):E189-97

In-hospital Pathway of Thrombolysis Data of Beijing Registry 2006 Arrival at the local hospital ECG Decision making Risk of thrombolysis, Biomarker Informed consent ED(64%) CCU(36%) PCI(18%) EM (71min) CCU (112min) 6 mins 40 mins 15 mins 7 mins 20 mins 50mins Total (83min) 6 mins 43 mins 17 mins Clin Invest Med. 2008,31(4):E189-97

The Chinese Consensus on Reperfusion Therapy for STEMI

Triage of Reperfusion strategy in hospital (Chinese Consensus) Suspected STEMI Time and risk Time of onset Risk of STEMI Risk of thrombolysis Delay of PCI PCI capable Non-PCI-capable 3-12 hours Transfer within 90 min Yes No < 3 hours In hospital fibrinolysis Primary PCI failed Successful Chin J Intern Med, 2009; 48:885 Rescue PCI angiography

Ongoing registry of ACS in China Web based registry Initiated in 2011 21 Centers STEMI and NSTEMI ACS 1500 patients before 7th Agu,2012 567 STEMI analysed

Reperfusion Treatment by Gender Preliminary analysis of Beijing ACS Registry 2012 No reperfusion Percentage of STMI (%) 100 80 60 40 20 19.6% 16.4% 64.4% 36.1% 5.1% 70.2% Thrombolysis PPCI 2006 (n=809) 2011 (n=567)

Pre-hospital Delay (symptom onset to hospital arrival) Preliminary analysis of Beijing ACS Registry 2012 >6hours 29 2-6 hours 28,6 <2 hours 42,4 0 10 20 30 40 50 Data not published

Delay of D to B in PPCI Preliminary analysis of Beijing ACS Registry 2012 Percentage of STMI (%) 40% Data not published

Trends of time delay in PPCI and Thrombolysis 180 2006 180 170 160 150 140 130 120 110 100 90 80 70 60 50 min 130 95.5 Symptom to D 117.5 104 D to N 137 Symptom to D 162 110 D to B 2012 Data not published

The rate of Pre-hospital ECG and EMS transport Preliminary analysis of Beijing ACS Registry 2012 Percentage of STMI (%) 50 40 30 20 10 Pre-hospital ECG EMS transport PPCI Thrombolysis No reperfusion 2006 2012 2006 2012

Reperfusion Treatment by Gender Preliminary analysis of Beijing ACS Registry 2012 No reperfusion Percentage of STMI (%) 100 80 60 40 20 20.4% 4.9% 74.8% 36.1% 5.8% 58.1% Thrombolysis PPCI Male (n=412) Female (n=155)

Door-to-reperfusion Time: Key Steps In Process Improvement Patients education Pre-hospital ECG STEMI Alert activated by ED physician Physician and Nurse Champions in the ED and Cath Lab Prompt and detailed data feedback report

Int J Cardiol. 2011 Nov 17;153(1):81-2.

Improvement of D to B in single PCI center in Beijing 2006 2011 Int J Cardiol. 2011 Nov 17;153(1):81-2.

Transfer for primary percutaneous coronary intervention in STEMI in Single PCI center in Shanghai Chinese Medical Journal 2008; 121(6):485-491

Summary The use of reperfusion therapy for STEMI varied across the country. Prehospital delay is still a big challenge. Primary PCI is the preferred treatment for STEMI in China. However, PPCI were not performed within the recommended time (90mins). Fibrinolytic therapy is still the choice of reperfusion and the in-hospital delay of fibrinolytic therapy needs to be improved. National network and regional programs is warranted to improve the optimal treatment and should be evaluated in the future.

THANK YOU!

The 23rd GWICC 11-14 Oct, 2012 Beijing WELCOME!